Evidence map›Paper›PMID 26195635›Full record

ArticleThe Journal of biological chemistry2015

Stanniocalcin-1 Potently Inhibits the Proteolytic Activity of the Metalloproteinase Pregnancy-associated Plasma Protein-A.

Søren Kløverpris, Jakob H Mikkelsen, Josefine H Pedersen, Malene R Jepsen, Lisbeth S Laursen, Steen V Petersen, Claus Oxvig

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The IGF System and Aging.Endocrine reviews · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Søren KløverprisFrom the Department of Molecular Biology and Genetics and.
Jakob H MikkelsenFrom the Department of Molecular Biology and Genetics and.
Josefine H PedersenFrom the Department of Molecular Biology and Genetics and.
Malene R JepsenFrom the Department of Molecular Biology and Genetics and.
Lisbeth S LaursenFrom the Department of Molecular Biology and Genetics and.
Steen V Petersenthe Department of Biomedicine, Aarhus University, DK-8000 Aarhus, Denmark.
Claus OxvigFrom the Department of Molecular Biology and Genetics and co@mbg.au.dk.
Aarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stanniocalcin-1 (STC1) is a disulfide-bound homodimeric glycoprotein, first identified as a hypocalcemic hormone important for maintaining calcium homeostasis in teleost fish. STC1 was later found to be widely expressed in mammals, although it is not believed to function in systemic calcium regulation in these species. Several physiological functions of STC1 have been reported, although many molecular details are still lacking. We here demonstrate that STC1 is an inhibitor of the metzincin metalloproteinase, pregnancy-associated plasma protein-A (PAPP-A), which modulates insulin-like growth factor (IGF) signaling through proteolytic cleavage of IGF-binding proteins (IGFBPs). STC1 potently (Ki = 68 pm) inhibits PAPP-A cleavage of IGFBP-4, and we show in a cell-based assay that STC1 effectively antagonizes PAPP-A-mediated type 1 IGF receptor (IGF1R) phosphorylation. It has recently been found that the homologous STC2 inhibits PAPP-A proteolytic activity, and that this depends on the formation of a covalent complex between the inhibitor and the proteinase, mediated by Cys-120 of STC2. We find that STC1 is unable to bind covalently to PAPP-A, in agreement with the absence of a corresponding cysteine residue. It rather binds to PAPP-A with high affinity (KD = 75 pm). We further demonstrate that both STC1 and STC2 show inhibitory activity toward PAPP-A2, but not selected serine proteinases and metalloproteinases. We therefore conclude that the STCs are proteinase inhibitors, probably restricted in specificity to the pappalysin family of metzincin metalloproteinases. Our data are the first to identify STC1 as a proteinase inhibitor, suggesting a previously unrecognized function of STC1 in the IGF system.

Indexed as

Blotting, WesternGlycoproteinsHEK293 CellsHumansInsulin-Like Growth Factor Binding Protein 4Intercellular Signaling Peptides and ProteinsPhosphorylationPregnancy-Associated Plasma Protein-AProteolysisReceptor, IGF Type 1Receptors, SomatomedinRecombinant ProteinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationGlycoproteinsIGF1R protein, humanInsulin-Like Growth Factor Binding Protein 4Intercellular Signaling Peptides and ProteinsPAPPA2 protein, humanPregnancy-Associated Plasma Protein-AReceptor, IGF Type 1Receptors, SomatomedinRecombinant ProteinsSTC2 protein, humanteleocalcindisulfideIGF-binding proteininsulin-like growth factor (IGF)metalloproteasemetzincinpappalysinprotease inhibitorproteolysisstanniocalcin

Identifiers

PMID26195635
PMCPMC4571946
OpenAlexW1901206160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.